Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome – a prospective randomized double-blind clinical trial

Table 4 Outcome measures

	Group 1	Group 2	P-value
Primary end points
Live Birth Rate (intention to treat), n (%)	14/34 (41.2)	21/37 (56.8)	0.19
Live Birth Rate (per protocol), n (%)	14/26 (53.8)	19/31 (61.3)	0.57
Secondary endpoint (per protocol)
Clinical Pregnancy rate, n (%)	15/26 (57.7)	22/31 (71.0)	0.29
Ongoing Pregnancy Rate, n (%)	15/26 (57.7)	19/31 (61.3)	0.79
Mild/Moderate OHSS, n (%)	1/26 (3.8)	3/31 (9.7)	0.62
Other end points (per protocol)
Mid-luteal ovarian volume (cm³)	77.6 ± 57.6	100.1 ± 60.4	0.13
Implantation rate, n (%)	17/38 (44.7)	30/58 (57.6)	0.44
Positive pregnancy rate, n (%)	19/26 (73.1)	25/31 (80.6)	0.49
Overall Miscarriage rates, n (%)	5/19 (26.3)	6/25 (24)	0.86
Clinical Miscarriage rate, n (%)	1/15 (6.7)	3/22 (13.6)	0.63

ISSN: 1757-2215